about
sameAs
FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancerTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyTrial watch: IDO inhibitors in cancer therapyCharacteristics of tertiary lymphoid structures in primary cancersThe structure of a human type III Fcgamma receptor in complex with FcTrial Watch-Oncolytic viruses and cancer therapyTertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic InterventionHigh cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinaseMutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndromeIsolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells.The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.Alternative complement pathway assessment in patients with atypical HUS.A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.Trial Watch: Toll-like receptor agonists in oncological indications.Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity.Th17 cells are involved in the local control of tumor progression in primary intraocular lymphoma.Trial Watch: Peptide-based anticancer vaccines.Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis.Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells.Classification of current anticancer immunotherapiesFc gamma receptors.Murine models of B-cell lymphomas: promising tools for designing cancer therapiesTrial watch: Naked and vectored DNA-based anticancer vaccinesInfluence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models.Trial Watch: Monoclonal antibodies in cancer therapyThe European Academy of Tumor Immunology: Bridging fields, continents and generations.Trial watch: Chemotherapy with immunogenic cell death inducersTumor microenvironment in NSCLC suppresses NK cells function.Trial Watch: Adoptive cell transfer immunotherapy.Trial Watch: Experimental Toll-like receptor agonists for cancer therapyPrognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).Presentation of antigen in immune complexes is boosted by soluble bacterial immunoglobulin binding proteins.Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Trial watch: Dendritic cell-based interventions for cancer therapyTrial watch: Prognostic and predictive value of the immune infiltrate in cancerTrial watch: Peptide vaccines in cancer therapy
P50
Q24634052-9B1FEF86-D464-42AA-B465-F646A1EA6166Q26993238-19E0A24F-87D9-49A0-B6FD-BEB1FA8EC3D6Q27004011-B2094926-E9B4-4BBF-BDEE-F5B7182AF04AQ27006866-FA27EB25-F337-4751-BF8F-0464D4947287Q27012852-AB8E43B3-B905-4916-9573-15E821453C5CQ27631148-2FF20320-EC1D-46BC-8900-DDA70AB1CDAFQ28072347-3E1EB58F-BC97-404F-9FD6-47AB8CBA9380Q28073895-723CC4B3-79FF-4E34-9BE9-7A5E2F9D327FQ28209500-C5A97139-34E4-4790-8482-55403A43566BQ28267924-30A49E5D-414C-46DC-BA0C-A328ED30E92DQ33309759-AA0CBCA0-77E0-44A8-8829-B8423C75E38CQ33384470-6B4166FA-826A-4F0D-93FD-54B16CCB2346Q33385299-0B13EBD6-0729-4104-B8B8-22220F0D8C51Q33393565-BFC5878F-0AA7-4967-AF28-0C197526AE7BQ33399198-62010C32-C6CF-47A7-A48D-67249D2750C2Q33402974-F92EEB03-4A12-4615-82CE-5C3A0109E93EQ33755300-83635B47-36C7-48F6-A627-514C9C4A33D9Q33878578-B1BF13E0-7D4D-4149-B38A-1C4513F1088DQ34002125-A8E76FD7-CB71-40C9-BB8D-FBF3987AD685Q34031403-4C2A4339-2D84-4C22-8580-5FDA55C08367Q34483345-6016B002-026D-401A-B392-BF6BF2D36E04Q34583801-A8093F41-4559-4FF4-B4C7-D957CCF0227BQ34825919-821BEA97-B00D-4CCC-81DF-E936AFE12235Q35149637-195561A0-83AD-445B-9110-489DD7E953B1Q35744700-A042E38C-655C-4219-BC6C-ACD11A9848AEQ35779492-DB97533F-DF6D-4266-9A0C-106686BD3A01Q35798986-8EF13C72-DFF3-4B67-B2F2-B230349593EBQ35931598-37AD8A40-CEDE-4B3C-A141-542459DF0BA2Q36038408-036A5F47-7CAA-44FD-9806-8BF417E6796BQ36038415-209F8BC8-E6CE-42F2-AECD-CAE2482626F9Q36038456-072671A0-A4CB-47EA-A854-763EDC7C6F35Q36038484-58E3EF49-7F71-4CD0-B8B6-D589263D5B1FQ36057432-1B0B8AE3-A7C9-452E-8559-B2205C299946Q36194849-0014BEF9-B7CE-4375-BB76-614D63C2994EQ36256382-BEEAF03F-B9A4-4F22-9D8A-DECC29FFDDDCQ36368050-5AD1D7C8-0883-4028-97F9-4EC00F50ED71Q36373370-2BA83B85-DD9E-4B8E-A583-C93BE59717D5Q36388529-7F72AC52-850C-4A6B-A3C0-C81F9D9C054FQ36456483-5F2A13F6-D565-4D86-ACC7-D772E9E85BAEQ36476100-A40386EB-A951-450E-B29A-C5D95F610756
P50
description
Forscher
@de
Frans immunologe
@nl
chercheur
@fr
hulumtuese
@sq
inmunóloga francesa
@ast
investigador
@es
researcher
@en
ricercatrice
@it
հետազոտող
@hy
研究者
@zh
name
Catherine Sautes-Fridman
@es
Catherine Sautes-Fridman
@nl
Catherine Sautès-Fridman
@ast
Catherine Sautès-Fridman
@ca
Catherine Sautès-Fridman
@en
Catherine Sautès-Fridman
@fr
Catherine Sautès-Fridman
@sl
type
label
Catherine Sautes-Fridman
@es
Catherine Sautes-Fridman
@nl
Catherine Sautès-Fridman
@ast
Catherine Sautès-Fridman
@ca
Catherine Sautès-Fridman
@en
Catherine Sautès-Fridman
@fr
Catherine Sautès-Fridman
@sl
altLabel
Catherine Fridman
@en
Catherine Sautes-Fridman
@ast
Catherine Sautes-Fridman
@en
catherine sautes-fridman
@en
prefLabel
Catherine Sautes-Fridman
@es
Catherine Sautes-Fridman
@nl
Catherine Sautès-Fridman
@ast
Catherine Sautès-Fridman
@ca
Catherine Sautès-Fridman
@en
Catherine Sautès-Fridman
@fr
Catherine Sautès-Fridman
@sl
P214
P268
P269
P2038
Catherine_Sautes-Fridman
P21
P213
0000 0000 0244 6656
P214
P268
P269
P27
P2798
P31
P496
0000-0003-1735-8722
P6634
catherine-sautes-fridman-65050010
P735
P7859
viaf-64330429